Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Sponsored by Corewell Health East
About This Study
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available in quantities sufficient to treat large numbers of infected people. Low doses of Naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as Ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms and prove an effective new treatment. This study will investigate their effectiveness in a randomized, blinded trial versus standard treatment plus placebo.
Conditions Studied
Interventions
- •Naltrexone
- •Ketamine
- •Placebo
Eligibility
View full eligibility criteria
Inclusion Criteria: * Positive for COVID -19 * Admitted to Beaumont Hospital - Royal Oak, Michigan * Age ≥18 * Receiving ≤ 6 liters/minute oxygen by nasal cannula for randomization to either placebo or naloxone arm OR receiving ≥ 6 liters/minute oxygen by nasal cannula or requiring advanced oxygenation for placement in ketamine arm Exclusion Criteria: * Known allergy to naltrexone * Known allergy to ketamine * Diagnosis of schizophrenia or psychosis * Pregnancy based on available medical history, existing labs, or verbal report * On chronic high dose opioids \> 90mg morphine mg equivalence * Use of naltrexone or Vivitrol within 90 days